Extension promotes innovative healthcare in the Netherlands
The €68 million investment will increase the pharmaceutical giant’s total production capacity by 60%. With an overall production capacity of more than 1.5 billion tablets per year, distributed to more than 100 countries, Abbott is the world’s leading manufacturer of dydrogesterone.
"Foreign companies and their investments are important for our country," said Minister Wiebes of Economic Affairs and Climate Policy. "Thanks to them, 1.4 million Dutch people have a job directly or indirectly. Therefore, I am very pleased that Abbott has opted for an expansion of its medicines production in the Netherlands. This investment not only underlines the long-term relationship between the Netherlands and Abbott, it also contributes to the further development of innovative healthcare in the Netherlands and beyond."
As the demand grows for quality medicines for women’s health, Abbott is continually investing to increase its production capacity in Weesp.
"We see an increasing demand for dydrogesterone in fast-growing countries like China, India or Russia," said Sieneke Bult, site director for Abbott’s plant in Weesp. "One of the medicines that we produce here in Weesp with dydrogesterone is a life-saving one. It has already had a lasting impact on the lives of millions of women worldwide by helping them get and stay pregnant."
Amsterdam: a centre for science
Founded in 1888 in the United States, the global pharmaceutical company manufactures a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. As well as dydrogesterone, Abbott manufactures two other products in Weesp: Duphalac (lactulose) and Influvac (influenza vaccine). With a global workforce of 99,000, around 1,700 Abbott employees work on sustainable solutions for unique health challenges at nine locations across the Netherlands.
In 2015, Abbott completed a new influenza factory in the Amsterdam Metropolitan Area, which increased its production capacity from 34 million doses to 54 million doses. Thanks to an investment in green hydropower energy, the site has reduced its Co2 emissions by over 50%.
The Amsterdam Metropolitan Area is a leading force in life sciences and health – and it keeps going from strength to strength. With numerous academic hospitals, universities, specialised research institutes − including the Netherlands Cancer Institute (NKI), the Sanquin Blood Supply Foundation and ACTA (one of the top dental education and research facilities in the world) − companies active in life sciences in the region enjoy superb access to innovative technologies, clinical trials, biobanks and centres of expertise. And, in 2019, the European Medicines Agency will move from London to Amsterdam. Amsterdam Science Park – one of Europe’s largest concentrations of high-level scientific education and research – is an important incubator of both businesses and young talent. Not to mention that increasingly more life sciences businesses are choosing the areas around Amsterdam Airport Schiphol and the Port of Amsterdam due to the potential of these outstanding logistics hubs.